Guardant Health sees FY25 revenue $850M-$860M, consensus $853.98M

Oncology revenue is expected to grow approximately 15% year over year in 2025. Excluding non-recurring, out of period revenue recorded in 2024, this range implies oncology revenue growth of approximately 20%. Oncology clinical volume is expected to accelerate to approximately 25% growth in 2025 compared to 20% growth in 2024. Screening revenue is expected to be in the range of $25 to $30 million, driven by 45,000 to 50,000 Shield test volume. Biopharma & data revenue growth is expected to be in the low double-digit range. Guardant Health (GH) expects full year 2025 non-GAAP gross margin to be in the range of 62% to 63%, compared to 62% in 2024. Guardant Health expects total non-GAAP operating expenses to be in the range of $815M-$825M, representing an 8 to 9% increase compared to 2024, due to the commercial ramp to support Shield while both R&D and G&A are expected to be approximately flat year over year. Guardant expects free cash flow burn to be in the range of $225M-$235M. This includes approximately $200M of screening net cash burn. Guardant Health expects the remainder of the business excluding screening to reach free cash flow breakeven in the fourth quarter of 2025.